Item Posts Archive - Page 12 of 1770 - Medivizor
Navigation Menu

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Posted by on Jun 11, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...

Read More

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Read More

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Posted by on Jun 11, 2023 in Lung cancer | 0 comments

In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...

Read More

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Read More

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Posted by on May 28, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients.  Some...

Read More